ACTA Fails To Become EU Law

BMI View: The European parliament's rejection of the Anti-Counterfeiting Trade Agreement (ACTA) is moderately bad news for innovative drugmakers but positive for generic drug producers that have operations within or through the EU but sell in developing markets.

To read the full article, please choose one of the following options: